TC Biopharm (Holdings) Plc (TCBP) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Motherwell, United Kingdom. El CEO actual es Bryan Leland Kobel.
TCBP tiene fecha de IPO 2022-02-11, 41 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $256.5K.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
